Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease.


Gliptins are accepted as a standard therapy for diabetes mellitus today. By inhibition of the enzyme dipeptidyl peptidase 4 (DPP4), gliptins prolong the GLP1-dependent insulin secretion in the pancreatic β-cells and thus support physiological blood glucose control. Various studies have now raised hope for an additional protective effect of pharmacological… (More)
DOI: 10.1093/ehjcvp/pvv044


7 Figures and Tables